Literature DB >> 15446306

A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome.

Armin Gerbitz1, Brian J Nickoloff, Krystyna Olkiewicz, Nicole E Willmarth, Gerhard Hildebrandt, Chen Liu, Lester Kobzik, Günther Eissner, Ernst Holler, James L M Ferrara, Kenneth R Cooke.   

Abstract

BACKGROUND: Idiopathic pneumonia syndrome (IPS) is a frequent and often fatal complication of allogeneic bone marrow transplantation (BMT). We have previously shown that experimental IPS is associated with alloreactive donor T cells and the inflammatory mediators TNF-alpha and lipopolysaccharide. Both TNF-alpha and lipopolysaccharide are known contributors to endothelial injury. Although damage to vascular endothelia has been associated with other complications after BMT, its relationship to lung injury has not been explored.
METHODS: We used a well-established murine BMT system, in which lung injury and graft-versus-host disease are induced by minor histocompatibility antigenic differences between donor and host, and the DNA terminal transferase nick-end labeling (TUNEL) procedure to evaluate whether significant pulmonary vascular endothelial cell (EC) apoptosis is present during the development of IPS.
RESULTS: Our data demonstrate that pulmonary histopathology after allogeneic BMT is accompanied by significant EC apoptosis and the appearance of activated caspase 3. Further evaluation reveals that EC injury coincides with the onset of pulmonary pathology, is associated with elevations in bronchoalveolar lavage fluid tumor necrosis factor (TNF)-alpha levels, and is accompanied by evidence for EC activation. Administration of a soluble TNF-alpha binding protein (recombinant human TNF-alpha receptor:Fc) from week 4 to week 6 after allogeneic BMT significantly reduces EC apoptosis and lung histopathology observed in this setting.
CONCLUSIONS: EC damage mediated by TNF-alpha is directly linked to the development of experimental IPS. Methods that protect or maintain the integrity of the pulmonary vascular endothelium may therefore prove effective in reducing the severity of lung injury after BMT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15446306     DOI: 10.1097/01.tp.0000128839.13674.02

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  Decreased asbestos-induced lung inflammation and fibrosis after radiation and bone marrow transplant.

Authors:  Jamie Levis; Roberto Loi; Kelly J Butnor; Pamela Vacek; Chad Steele; Brooke T Mossman; Daniel J Weiss
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-02       Impact factor: 6.914

2.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 3.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

4.  TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).

Authors:  Gregory A Yanik; Stephan A Grupp; Michael A Pulsipher; John E Levine; Kirk R Schultz; Donna A Wall; Bryan Langholz; Christopher C Dvorak; Keith Alangaden; Rakesh K Goyal; Eric S White; Jennifer M Collura; Micah A Skeens; Saada Eid; Elizabeth M Pierce; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Translational research efforts in biomarkers and biology of early transplant-related complications.

Authors:  Sophie Paczesny; Maribel Diaz-Ricart; Enric Carreras; Enrique Carerras; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

6.  Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage.

Authors:  N K Rathi; A R Tanner; A Dinh; W Dong; L Feng; J Ensor; S K Wallace; S A Haque; G Rondon; K J Price; U Popat; J L Nates
Journal:  Bone Marrow Transplant       Date:  2014-12-22       Impact factor: 5.483

7.  Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation.

Authors:  Daniela M Schlatzer; Jean-Eudes Dazard; Rob M Ewing; Serguei Ilchenko; Sara E Tomcheko; Saada Eid; Vincent Ho; Greg Yanik; Mark R Chance; Kenneth R Cooke
Journal:  Mol Cell Proteomics       Date:  2012-02-15       Impact factor: 5.911

8.  Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation.

Authors:  Antiopi Varelias; Kate H Gartlan; Ellen Kreijveld; Stuart D Olver; Mary Lor; Rachel D Kuns; Katie E Lineburg; Bianca E Teal; Neil C Raffelt; Melody Cheong; Kylie A Alexander; Motoko Koyama; Kate A Markey; Elise Sturgeon; Justine Leach; Pavan Reddy; Glen A Kennedy; Gregory A Yanik; Bruce R Blazar; Siok-Keen Tey; Andrew D Clouston; Kelli P A MacDonald; Kenneth R Cooke; Geoffrey R Hill
Journal:  Blood       Date:  2015-02-11       Impact factor: 22.113

9.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

Review 10.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.